{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:59:21Z","timestamp":1787065161745,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaip.2024.09.012","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:44:59Z","timestamp":1726764299000},"page":"2934-2944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current Goals of NSAID-ERD Management: Patient-Centered Approaches Involving NSAID Desensitization With and Without Biologics"],"prefix":"10.1016","volume":"12","author":[{"given":"Irina","family":"Bobolea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9846-7850","authenticated-orcid":false,"given":"Jan","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Sanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.09.012_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib2","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0272-5231(21)00582-7","article-title":"Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter\u2019s syndrome","volume":"9","author":"Zeitz","year":"1988","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"European Network on Aspirin-Induced Asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.09.012_bib5","series-title":"Praktische Allergologie \u2013 Schwerpunkt HNO-Heilkunde","first-page":"233","article-title":"Pseudo-allergic reactions on non-steroidal antiinflammatory drugs (in German)","author":"Schapowal","year":"1998"},{"key":"10.1016\/j.jaip.2024.09.012_bib6","article-title":"Aspirin-exacerbated respiratory disease is associated with variants in filaggrin, epithelial integrity, and cellular interactions","volume":"3","author":"Jerschow","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2024.09.012_bib7","first-page":"447","article-title":"Aspirin sensitivity in patients with moderate to severe asthma","volume":"19","author":"Arshi","year":"2020","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.012_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy","volume":"147","author":"Stevens","year":"2020","journal-title":"Asthma & Immunology. J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4168\/aair.2015.7.4.312","article-title":"Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?","volume":"7","author":"Kowalski","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2024.09.012_bib12","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/bmj.1.5949.67","article-title":"Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients","volume":"1","author":"Szczeklik","year":"1975","journal-title":"Bri Med J"},{"key":"10.1016\/j.jaip.2024.09.012_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0091-6749(77)90106-3","article-title":"Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis","volume":"60","author":"Szczeklik","year":"1977","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1164\/ajrccm.160.1.9808048","article-title":"Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics","volume":"160","author":"Picado","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2021.08.015","article-title":"Eicosanoid dysregulation and type 2 inflammation in AERD","volume":"148","author":"Mullol","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib20","first-page":"384","article-title":"Prevalence of chronic rhinosinusitis with nasal polyps in Catalonia (Spain): a retrospective, large-scale population-based study","volume":"60","author":"Sanchez-Collado","year":"2022","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.012_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2020.01.013","article-title":"Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis","volume":"124","author":"Staudacher","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib22","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib23","first-page":"151","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.012_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2024.09.012_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1398-9995.1993.tb04754.x","article-title":"Position paper: immunotherapy","volume":"48","author":"Mailing","year":"1993","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib26","first-page":"461","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023\u2014published by the German Respiratory Society (DGP) e. V [in German]","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.jaip.2024.09.012_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.wjorl.2020.07.009","article-title":"Aspirin-exacerbated respiratory disease: update on medical management","volume":"6","author":"White","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2024.09.012_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jaip.2022.01.039","article-title":"SWOT Analysis of Chronic Rhinosinusitis Care Anno 2022","volume":"10","author":"Hellings","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(21)00457-4","article-title":"Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial","volume":"10","author":"Lourijsen","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11882-024-01154-w","article-title":"Systematic review of long term sinonasal outcomes in CRSwNP after endoscopic sinus surgery: a call for unified and standardized criteria and terms","volume":"24","author":"Rodriguez-Van Strahlen","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2024.09.012_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/alr.21182","article-title":"A\u00a0systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis","volume":"3","author":"Vashishta","year":"2013","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib33","first-page":"17","article-title":"Inhalative Provokation mit Lysin-Azetylsalizyls\u00e4ure bei Analgetika-Asthme-Syndrom","volume":"36","author":"Schmitz-Schumann","year":"1982","journal-title":"Prax Klin Pneumol"},{"key":"10.1016\/j.jaip.2024.09.012_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0091-6749(96)70123-9","article-title":"Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes","volume":"98","author":"Stevenson","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0091-6749(90)90222-P","article-title":"Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma","volume":"85","author":"Sweet","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00106-015-0008-7","article-title":"ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis: Differentialdiagnostik und Therapie","volume":"63","author":"Kirsche","year":"2015","journal-title":"Hno"},{"key":"10.1016\/j.jaip.2024.09.012_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11882-014-0441-9","article-title":"Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?","volume":"14","author":"Klimek","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2024.09.012_bib39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.iac.2009.07.008","article-title":"Aspirin intolerance: does desensitization alter the course of the disease?","volume":"29","author":"Klimek","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2024.09.012_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00063198-200401000-00009","article-title":"Aspirin intolerance and the cyclooxygenase-leukotriene pathways","volume":"10","author":"Szczeklik","year":"2004","journal-title":"Curr Opin Pulmon Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1398-9995.1984.tb02621.x","article-title":"Aspirin tolerance induced in aspirin-sensitive asthmatics","volume":"39","author":"Kowalski","year":"1984","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.734733","article-title":"Pathomechanisms of AERD\u2014recent advances","volume":"2","author":"Lyly","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.201809-1755OC","article-title":"Unique effect of aspirin therapy on biomarkers in aspirin-exacerbated respiratory\u00a0disease. A prospective trial","volume":"200","author":"Cahill","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib44","first-page":"445","article-title":"The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data","volume":"277","author":"San","year":"2019","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2024.09.012_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/ajrccm\/140.1.148","article-title":"Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma","volume":"140","author":"Arm","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2024.09.012_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/01.MLG.0000166702.38850.1B","article-title":"Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial","volume":"115","author":"Parikh","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2024.09.012_bib47","author":"Simon"},{"key":"10.1016\/j.jaip.2024.09.012_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.all.0000225153.45027.6a","article-title":"Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements","volume":"6","author":"Pfaar","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib49","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1136\/thorax.55.suppl_2.S75","article-title":"Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies","volume":"55","author":"Nucera","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.09.012_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/1744666X.2014.901889","article-title":"Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis","volume":"10","author":"Parikh","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib51","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00405-021-07063-2","article-title":"A\u00a0retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease","volume":"279","author":"Pendolino","year":"2021","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2024.09.012_bib52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/alr.22168","article-title":"Alcohol-induced respiratory symptoms improve after aspirin desensitization in patients with aspirin-exacerbated respiratory disease","volume":"8","author":"Glicksman","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/all.12131","article-title":"Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease","volume":"68","author":"Fruth","year":"2013","journal-title":"Allergy"},{"issue":"3 p preceding table of contents","key":"10.1016\/j.jaip.2024.09.012_bib56","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2012","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"key":"10.1016\/j.jaip.2024.09.012_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40629-022-00220-x","article-title":"Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)\u2014recommendations by German allergy and ORL societies AeDA and DGHNO for dupilumab, omalizumab, and mepolizumab","volume":"31","author":"Klimek","year":"2022","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib58","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib59","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.012_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40629-018-0087-6","article-title":"Comparison of extended intervals and dose reduction of omalizumab for asthma control","volume":"28","author":"B\u00f6lke","year":"2019","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s40629-023-00244-x","article-title":"Patients with asthma consulting an allergist differ from those consulting a pulmonologist","volume":"32","author":"Ciprandi","year":"2023","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40629-016-0093-5","article-title":"Novel strategies for the treatment of asthma","volume":"25","author":"Lommatzsch","year":"2016","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40629-018-0079-6","article-title":"What\u2019s new in the Global Initiative for Asthma 2018 report and beyond","volume":"28","author":"Ong","year":"2019","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40629-018-0051-5","article-title":"A\u00a0century of \u201cintrinsic asthma\u201d","volume":"27","author":"Rothe","year":"2018","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s40629-014-0028-y","article-title":"Bronchial asthma: is personalized therapy on the horizon?","volume":"23","author":"Taube","year":"2014","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40629-017-0048-5","article-title":"Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities","volume":"27","author":"Koennecke","year":"2018","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2024.09.012_bib67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00106-024-01433-y","article-title":"Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization: results of a multicentric study","volume":"72","author":"Staufenberg","year":"2024","journal-title":"HNO"},{"key":"10.1016\/j.jaip.2024.09.012_bib68","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib69","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib70","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease\u2014how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031031","article-title":"Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study","volume":"101","author":"Bertlich","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2024.09.012_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027471","article-title":"Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab","volume":"100","author":"Bertlich","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2024.09.012_bib73","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.012_bib74","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib75","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib76","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.012_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib78","first-page":"133","article-title":"Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease","volume":"25","author":"Guillen","year":"2015","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib79","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib80","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.09.012_bib82","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial","volume":"11","author":"Sanchez","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib83","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib84","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2020.08.008","article-title":"Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease","volume":"126","author":"Laidlaw","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib87","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alr.22643","article-title":"Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease","volume":"11","author":"Sweis","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib89","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1939-4551-7-18","article-title":"Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease","volume":"7","author":"Howe","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2024.09.012_bib92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib93","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.09.012_bib94","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jaip.2018.12.014","article-title":"Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease","volume":"7","author":"Jerschow","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib95","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib96","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/alr.22709","article-title":"Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: clinical perspective","volume":"11","author":"Bosso","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaip.2023.09.019","article-title":"Should biologics be used before aspirin desensitization in aspirin-exacerbated respiratory disease?","volume":"12","author":"Laidlaw","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib98","first-page":"48","article-title":"Therapie der chronischen Rhinosinusitis mit Nasenpolypen","volume":"14","author":"Lux","year":"2022","journal-title":"Umw\u00e4lzungen durch Biologika"},{"key":"10.1016\/j.jaip.2024.09.012_bib99","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s15007-022-5643-1","article-title":"KBV bewertet verschiedene Biologika als gleichwertig","volume":"31","author":"Klimek","year":"2022","journal-title":"Allergo J"},{"key":"10.1016\/j.jaip.2024.09.012_bib100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-020-00910-y","article-title":"A\u00a0critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis","volume":"20","author":"Brown","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2024.09.012_bib101","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jaip.2022.02.017","article-title":"Biologicals and endoscopic sinus surgery for severe uncontrolled chronic rhinosinusitis with nasal polyps: an economic perspective","volume":"10","author":"van der Lans","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib103","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib104","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2021.10.029","article-title":"Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"149","author":"Scadding","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib106","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib107","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.012_bib108","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib109","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.012_bib110","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib111","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.012_bib112","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2023.01.008","article-title":"Toward a predict and prevent approach in obstructive airway diseases","volume":"11","author":"Couillard","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824009383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824009383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:40:41Z","timestamp":1732117241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824009383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2213219824009383"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.09.012","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Goals of NSAID-ERD Management: Patient-Centered Approaches Involving NSAID Desensitization With and Without Biologics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}